Please provide your email address to receive an email when new articles are posted on . At 2 years, 74% of Black patients and 66.4% of white patients who received ranibizumab achieved vision of 20/40 ...
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today new, five-year efficacy, safety and durability data from the Phase ...
The ranibizumab ocular implant (Susvimo) reduces the need for frequent intravitreal anti-VEGF injections in patients with neovascular age-related macular degeneration or diabetic macular edema, and ...
– Susvimo can help people with diabetic retinopathy (DR) maintain their vision and prevent progression to blindness with only one treatment every nine months – – Susvimo’s innovative technology via ...
Bevacizumab may be preferable to ranibizumab in the treatment of retinopathy of prematurity in as far as it is associated with a lower risk of retreatment. Patients with retinopathy of prematurity ...
Continuous administration of ranibizumab with a port delivery system provides an alternative to frequent intravitreal injections for diabetic macular edema and helps delay progression of ...
Susvimo was nonferior to intravitreal ranibizumab based on the change from baseline in distance best corrected visual acuity score. The Food and Drug Administration (FDA) has approved Susvimo ® ...
Weight loss pills and injections are two forms of medication used to help people lose weight. There are a number of medications approved for weight loss and they can work in a variety of ways, such as ...
Ranibizumab implants approved by FDA for DME offer a more convenient treatment schedule, reducing injection frequency significantly. The phase 3 Pagoda study showed noninferior visual acuity with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback